A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF NEW AND TRADITIONAL ANTIHYPERTENSIVE DRUGS IN RESISTANT HYPERTENSION
Main Article Content
Keywords
Resistant hypertension; mineralocorticoid receptor antagonist; SGLT2 inhibitor; antihypertensive therapy; randomized controlled trial.
Abstract
Background: Resistant hypertension poses a significant clinical challenge, affecting approximately 10-15% of hypertensive patients worldwide. Despite optimal therapy with three or more antihypertensive agents, blood pressure control remains suboptimal in this population.
Objective: This randomized controlled trial aimed to compare the efficacy and safety of a novel antihypertensive combination (mineralocorticoid receptor antagonist plus SGLT2 inhibitor) versus traditional triple therapy in patients with resistant hypertension.
Methods: One hundred patients with resistant hypertension were randomly allocated to either the new drug combination group (n=50) or traditional therapy group (n=50). The primary outcome was reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after 12 weeks of treatment. Secondary outcomes included achievement of target blood pressure (<140/90 mmHg) and adverse events profile.
Results: At 12 weeks, the new drug combination demonstrated superior SBP reduction compared to traditional therapy (32.4 ± 8.6 mmHg vs 24.1 ± 9.2 mmHg, p=0.001). DBP reduction was also significantly greater in the new drug group (18.7 ± 6.4 mmHg vs 13.2 ± 7.1 mmHg, p=0.002). Target blood pressure achievement was higher in the new combination group (68% vs 46%, p=0.026). The incidence of adverse events was comparable between groups (24% vs 28%, p=0.639).
Conclusion: The novel combination of mineralocorticoid receptor antagonist with SGLT2 inhibitor demonstrated superior efficacy in reducing blood pressure and achieving treatment targets in resistant hypertension compared to traditional triple therapy, with a comparable safety profile.
References
2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-526. PMID: 18574054
3. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-e90. PMID: 30354828
4. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-1642. PMID: 22379110
5. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. PMID: 30165516
6. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355-361. PMID: 25156625
7. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-845. PMID: 17309946
8. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. PMID: 26414968
9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. PMID: 26378978
10. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262-275. PMID: 24602971
11. Georgianos PI, Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2017;3(1):78-88. PMID: 29340316
12. Sinnott SJ, Smeeth L, Williamson E, Douglas IJ. Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015. BMJ. 2017;358:j3984. PMID: 28912000
13. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257-263. PMID: 25368026
14. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44(1):1-85. PMID: 17364688
15. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180-1193. PMID: 26343814
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Amarnath B R
Assistant Professor, Department of Pharmacology, Index Medical College, Hospital and Research Centre, Indore, Madhya Pradesh, India
Prabhavathi Kotni
Assistant Professor, Department of Pharmacology, Index Medical College, Hospital and Research Centre, Indore, Madhya Pradesh, India
Akash Vishwe
Assistant Professor, Department of Pharmacology, Index Medical College, Hospital and Research Centre, Indore, Madhya Pradesh, India
